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ABSTRACT 
Rheumatoid arthritis (RA) is a chronic inflammatory disease which leads to joint damage and 
bone destruction, with a complex interplay of genetic and environmental factors involved in its 
etiology. RA is more common among women than men at all ages, but the gender difference 
seems to be highest before menopause. It has been hypothesized that changes in female hormonal 
levels might have a role in RA pathogenesis. The overall aim of this thesis was to study the 
association between hormonal/reproductive factors and the risk of RA and to determine whether 
these factors were differently associated with serological phenotypes of the disease (according to 
the presence/absence of anti-citrullinated peptides antibodies (ACPA) and rheumatoid factor 
(RF)).  
This thesis is based on information from two large studies. Three articles were based on the 
Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA), a population-based case-
control study comprising incident RA cases. The study population were people aged 18 and 
above, living in diverse geographical parts of Sweden from 1996. Controls were randomly 
selected from the population register and matched to the cases by age, sex and residential area. 
Cases and controls completed an extensive questionnaire, collecting information about life-
style/environmental exposures. One article was based on the Nurses’ Health Study (NHS), which 
consists of two prospective cohorts of female nurses in the USA. Data collection started in 1976 
(women aged 30-55 years) and 1989 (women aged 25-42 years). Both cohorts of the NHS were 
followed via biennial questionnaires about diseases, lifestyle and health practices. 
According to our results, parous women had an increased risk of ACPA-negative RA compared 
with nulliparous women, aged 18-44 years. The increased risk was attributable to an elevated risk 
during the postpartum period, and to a young age at first birth. Older age at first birth seemed to 
be associated with a decreased risk of ACPA-positive RA. Parous women who breastfed for more 
than a year had a decreased risk of ACPA-positive RA compared with parous women who 
breastfed for up to 6 months. This decreased risk was non-significant after adjustment for 
smoking. Ever oral contraceptive use was significantly associated with a decreased risk of ACPA-
positive RA, while a longer duration of use was significantly associated with a decreased risk for 
both RA subsets. Postmenopausal women had an increased risk of seronegative RA, but they had 
no association with the onset of seropositive RA. Women with a long duration of postmenopausal 
hormone therapy (PMH) had an increased risk of seropositive RA in the NHS. Finally, in the 
EIRA study, postmenopausal women who were currently using PMH at onset of their disease had 
a decreased risk of ACPA-positive RA. This decreased risk was mainly observed among women 
aged 50-59 years, with a short duration of use (<7 years), and only among users of a combined 
therapy of estrogen and progestogens.  
Further research is required to explore the biological mechanisms behind our findings, but our 
results contribute to the knowledge of hormonal/reproductive factors, and their impact on the 
serological phenotypes of RA.  
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1 INTRODUCTION 
1.1 RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, a criteria-based 
syndrome with a multifactorial etiology. It is characterized by symmetrical inflammation of 
the small joints and eventual bone destruction. [1] The introduction of biological treatment, 
which has replaced the classical disease modifying anti-rheumatic drugs, has greatly 
improved the management of the disease. [2] Nevertheless, RA remains an important chronic 
disorder, with reduced life expectancy and increased mortality from infections and 
cardiovascular and respiratory diseases. [3] 
The occurrence of RA seems to have important geographical variation. The median annual 
incidence has been found to range from 16.5 in southern European countries, to 29 in 
northern European countries, and up to 38 cases per 100,000 in North America. [4] Using 
data from a nationwide register-based study in Sweden, the incidence of RA was estimated to 
be 41 per 100,000 (56 and 25 per 100,000 for women and men respectively). [5]  
RA is two to three times more common among women, with an estimated disease prevalence 
of 2.0-2.7 percent in women above 60 years of age. [6] A higher incidence of RA is seen 
among women compared to men across all ages, [7-9] but the difference is greater during the 
reproductive years. [7, 8] The highest incidence among women has been reported between 
55-64 years of age, during the peri- or postmenopausal stages. [7, 9] These gender differences 
have led to the hypothesis that hormonal factors are important in disease development.  
 
1.2 RISK FACTORS FOR RA 
1.2.1 Autoantibodies in RA 
Autoantibodies, mostly detected in the serum, are useful in the diagnosis, prognosis and 
follow-up of patients with rheumatic diseases. [10]  
Rheumatoid factor (RF) can be found in approximately 75% of RA patients, but its 
specificity is limited as it can also be present in patients with other autoimmune diseases (e.g. 
Sjögren’s syndrome), infectious diseases, and even in healthy population. The presence of RF 
has been widely used as a diagnostic marker of RA in spite of its low specificity, [11] and 
was part of the 1987 American College of Rheumatology (ACR) criteria for RA diagnosis 
(Table 1). [12]  
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Table 1. The 1987 revised criteria for the classification of rheumatoid arthritis* [12] 
1. Morning stiffness 
2. Arthritis of 3 or more joint areas 
3. Arthritis of hand joints 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Serum rheumatoid factor 
7. Radiographic changes 
* The patient should satisfy at least 4 of these 7 criteria to be classified as an RA case 
 
Anti-citrullinated protein antibodies (ACPA) are among the latest markers for the diagnosis 
of RA, showing a higher specificity than the classic RF. [13] Moreover, emerging data 
suggest that ACPAs would be able to predict the development of early or undifferentiated 
RA, the severity in established RA, and the onset of RA in certain high-risk populations. [14] 
In 2010, new criteria were introduced which included ACPA-status, together with RF (Table 
2). [15] RF and ACPAs overlap to a considerable extent. [16, 17] 
 
Table 2. The 2010 ACR/EULAR European League against Rheumatism classification 
criteria for rheumatoid arthritis [15] 
Classification criteria for RA (score-based algorithm: add scores of categories A-D; 
a score of ≥6/10 is needed for classification of patient as having definite RA 
Score 
A.  Joint involvement  
      1 large joint 0 
      2-10 large joints 1 
      1-3 small joints (with or without involvement of large joints) 2 
      4-10 small joints (with or without involvement of large joints) 3 
      >10 joints (at least 1 small joint) 5 
B.  Serology (at least 1 result is needed for classification)  
      Negative RF and negative ACPA 0 
      Low-positive RF or low-positive ACPA  2 
      High-positive RF or high-positive ACPA 3 
C.  Acute phase reactants (at least 1 test result is needed for classification)  
      Normal CRP and normal ESR 0 
      Abnormal CRP or abnormal ESR 1 
D.  Duration of symptoms  
      <6 weeks 0 
      ≥6 weeks 1 
ACR= American college of Rheumatology; EULAR= European League against 
Rheumatism; CRP=C-reactive protein, ESR=erythrocyte sedimentation rate 
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According to emerging evidence, ACPA-positive and ACPA-negative RA have different 
environmental and genetic risk factors; this supports the notion of RA as two different disease 
entities with different/distinct etiologies.  Few risk factors have been identified for the ACPA-
negative subgroup of RA, except for obesity. [18, 19] 
1.2.2 Genetic risk factors 
Twin studies in RA have demonstrated a low concordance in monozygotic twins, ranging 
between 12% and 30%. [20-23] This suggests that environmental factors play a fundamental 
role in the etiology of the disease. 
Genetic risk factors for RA include the human leukocyte antigen (HLA) region, specifically 
the HLA-DRB1 shared epitope (SE) alleles, and the PTPN22 gene.  It is interesting that these 
genetic factors have been mainly associated with the risk of ACPA-positive RA. [24-26]  
1.2.3 Environmental risk factors 
Apart from the well-described association between smoking and increased risk of developing 
RA, [17, 27-29] several other environmental exposures have been explored with regard to the 
risk of developing RA, including for example alcohol consumption, [30, 31] body mass index 
(BMI), [18, 32, 33] and exposure to silica. [34-36] The striking gender difference in the 
occurrence of disease has led to the hypothesis that hormonal/reproductive factors are 
involved in the etiology of RA. Several studies have investigated these factors, especially oral 
contraceptive (OC) use; however it is notable that most have not taken into consideration 
ACPA-status or genetic factors. 
1.2.3.1 Parity 
The gender difference in RA incidence seems to be higher during the reproductive years, with 
a female/male ratio of 3-6:1. [7, 8] In pre-established RA an amelioration of symptoms 
during pregnancy followed by a postpartum flare has been well described, [37-39] suggesting 
an involvement of reproductive factors in the etiology. A decreased RA incidence has been 
observed during pregnancy, followed by an increase after delivery. The increased risk of RA 
has been observed during the first three months up to 2 years postpartum, [40-42] while 
parous women seem to have no increased, [43-46] or even decreased risk of RA in the long 
term. [47-49] With regard to the effect of number of children [43-45, 47, 49] and age at first 
birth on RA risk, [43-45, 47, 48] no consensus has been reached.   
1.2.3.2 Breastfeeding and OC use 
Breastfeeding (BF) has been associated with a decreased risk of RA, [44, 46, 50] with the 
strongest association among those with a long history of BF. [44] Other studies, however, 
have reported an elevated disease risk. [51, 52] A recent meta-analysis showed a relative risk 
of 0.68 (95% CI 0.49-0.92) based on data from six published studies. [44, 46, 50, 51, 53, 54] 
The different impact of BF on the subsets of RA has not been investigated.  
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No association between OC use and the risk of RA could be demonstrated in the majority of 
studies, [42, 44, 46, 49, 51, 55-59] including two recent meta-analyses. [60, 61] A few studies 
have shown an inverse association, [62-67] including one study in which a larger effect with 
a longer duration of use was demonstrated. [51]  To our knowledge, no study has included 
ACPAs in a stratified manner but only as a confounder, when investigating the association 
between OC use and RA. 
1.2.3.3 Menopausal factors 
It has been suggested that the menopausal transition, a time with notorious hormonal 
changes, might be involved in RA pathogenesis though the evidence is limited. [68] An early 
menopause (<45 years of age) has been associated with an increased risk of RA, which was 
more pronounced for seronegative RA than for seropositive RA. [69] As with other 
environmental factors, menopausal factors may also be associated differently with the two 
subgroups of disease, but most previous studies were conducted without stratification into 
seronegative/seropositive RA phenotypes.   
1.2.3.4 Postmenopausal hormone therapy 
The use of postmenopausal hormone therapy (PMH) for menopause-related symptoms in 
relation to RA risk has been explored in several studies, most of them showing no association 
[44, 59, 62, 70-76] while a few have reported an increased [57] or decreased risk of 
developing RA. [77, 78] In one study, findings indicated that the use of PMH among women 
carrying the HLA-DRB1 SE alleles may protect against the development of ACR criteria-
defined RA in a population with early undifferentiated arthritis, and that this protection is 
associated with a reduction in ACPA levels. [77] Nevertheless, to our knowledge, no study 
has investigated the association between PMH and the risk of ACPA-positive as compared to 
ACPA-negative RA in a setting in which exposure to PMH was ascertained in a healthy 
population. 
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2 AIMS  
 
2.1 GENERAL AIM 
 
The general aim of this thesis was to study the association between hormonal/reproductive 
factors and the risk of developing RA among women. A further aim was to determine 
whether these factors were differently associated with serological phenotypes of the disease 
(ACPA-positive/-negative RA and RF-positive/-negative RA). Specific factors of interest 
were investigated in four separate studies (Papers I-IV). 
 
2.2 SPECIFIC AIMS 
 
 Paper I: To study the association between parity and the risk of developing RA. 
 Paper II: To study the association between both BF history and OC use and the risk of 
developing RA. 
 Paper III: To investigate whether menopausal factors are associated with subsequent 
development of serological RA phenotypes. 
 Paper IV: To study the association between use of PMH and the risk of developing RA. 
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3 MATERIALS AND METHODS 
3.1 STUDY BASE 
Three out of four studies included in this thesis (Papers I, II and IV) were based on the 
Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA), a population-based 
case-control study comprising the population, aged 18 years and above, living in central and 
southern Sweden. Data collection started in 1996 and is still on-going. So far, 3724 cases and 
5935 controls have participated in EIRA; of these, 2809 cases and 4250 controls are women 
(data until September 2014). The participation rate among women for the complete study 
period is 95% among cases and 80% among controls. The observation periods ended in 2009 
(Paper I), 2011 (Paper IV) and 2014 (Paper II). 
                                 
 
For one of the studies (Paper III) we utilized data from the Nurse’s Health study (NHS), 
which consists of two prospective cohorts. Data collection in the first cohort (NHS) started in 
1976 and included 121,700 female nurses, aged 30-55 years, and followed through 2010. The 
second cohort (NHSII) started in 1989 and included 116,430 female nurses, who were 
younger at baseline (aged 25-42 years, born between 1947 and 1964) and followed through 
2011. In total, 1096 incident RA cases have so far been identified. 
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3.2 STUDY DESIGN 
3.2.1 Case identification and selection of controls 
Papers I, II and IV: Incident cases were diagnosed by rheumatologists according to the 1987 
ACR criteria for RA. [12] During the conduction of the studies included in this thesis, new 
criteria for case diagnosis were published in 2010; however, only a small fraction of cases in 
our studies (Papers II and IV) have been diagnosed with only these more recent criteria [15] 
and not with the original criteria. [12]  
At the beginning of the EIRA study (1996-2006), one control was selected for each case, 
matched by sex, age and residential area. In a second phase (2006 to the present), two 
controls were selected for each case (Figure 1). Controls were randomly selected from the 
population, using the national population register which is continuously updated and covers 
the total population in Sweden. All study subjects were required to speak in Swedish. If a 
selected control could not be contacted or refused to participate, another control was invited 
to participate. At an early stage, some cases not fulfilling the ACR criteria were included with 
the purpose of investigating undifferentiated arthritis. Although these cases were eventually 
excluded, their controls were still included in order to increase power. 
 
Figure 1. Phases of the EIRA study over time. 
 
* Overall participation rate for men and women combined.                         
EIRA=Epidemiological Investigation of Rheumatoid Arthritis. 
 
Paper III: The identification of RA cases has previously been described in detail. [44] Briefly, 
case identification was a two-stage procedure in which a Connective Tissue Disease 
Screening Questionnaire (CSQ) [79] was sent to individuals with a physician’s diagnosis of 
RA based on self-reported information. The medical records of those who screened positive 
1996-2006 
• 1 control per case 
• ACR criteria 1987 
• Inclusion of controls 
from cases who did 
not fulfill ACR 
criteria. 
• Participation rate*: 
95% cases/81% 
controls 
2006- to date 
• 2 controls per case 
• ACR criteria 
1987/2010 
• New questions (e.g. 
food intake, 
breastfeeding, 
postmenopausal 
hormone therapy, etc) 
• Participation rate*: 
92% cases/73% 
controls  
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were reviewed by two board-certified rheumatologists in order to confirm RA according to 
the 1987 ACR classification criteria. [12] 
3.2.2 Data collection 
For the EIRA study, an identical questionnaire was given to the cases shortly after diagnosis 
and sent to the controls by mail, in order to collect information on a broad range of 
environmental and life-style factors. In 2006, a new version of the questionnaire was 
released, including new questions for example on food intake (Figure 1). Participating cases 
and controls were also asked to provide a blood sample for serological and genetic analyses.  
Both cohorts of the NHS were followed via biennial questionnaires regarding diseases, 
lifestyle and health practices. The participation rate has been high with <10% of cases lost to 
follow-up. [80] The questions on hormonal/reproductive factors are extensive and include OC 
use, menopausal status, parity, miscarriage, age at menarche and regularity of menses, among 
many others. Participants were asked to provide blood samples for serological analyses.  
3.2.3 Serological analyses  
Papers I, II and IV: Blood samples were assayed for ACPA-status using the Immunoscan-RA 
Mark2 ELISA test (Euro-Diagnostica, Malmö, Sweden). [81, 82] The cut-off value for 
ACPA-positive RA was 25 U/ml. Cases that lacked information on ACPA-status were 
excluded from the analyses (28 and five cases for Papers I and IV respectively; for Paper II, 
35 and 13 cases were excluded for OC use and BF analyses respectively). 
Paper III: Information on RF and ACPA (available since 1990) was collected from medical 
records reviewed from the date of RA diagnosis. The DIASTAT CCP (Axis-Shield 
Diagnostics, Dundee, UK) second-generation test, a semiquantitative/qualitative ELISA, was 
used for the detection of ACPAs. [83] A titer >5 U/ml was considered positive according to 
the manufacturer’s established threshold. Seropositive RA was then defined as RF-positive or 
ACPA-positive, while seronegative RA was defined as RF-negative and ACPA-negative. 
 
3.3 ENVIRONMENTAL EXPOSURES AND THE RISK OF RA 
Papers I, II and IV: For each case, the year when the first symptoms of RA occurred was 
defined as the index-year and the same index-year was used for the corresponding control. 
3.3.1 Parity 
Parous women were defined as those who had given birth before or during the index-year. 
Women who had not given birth before or during the index-year were considered nulliparous. 
The postpartum period was defined as 0 (if both childbirth and RA onset occurred during the 
index-year), 1, or 2 (if there were 1 year or 2 years, respectively, between the most recently 
born child and the index-year).  
  9 
Age at first birth was obtained for women in their reproductive years (aged 18-44 years) and 
was categorized according to the quartiles among the controls (≤22, 23-26, 27-30 and ≥31 
years). The number of children was categorized as 1, 2, 3 and ≥4. 
3.3.2 BF and OC use 
Total BF history among parous women was calculated as the sum of the duration of BF for 
each delivered child and categorized as 0-6, 7-12 and ≥13 months. Parous women who did 
not breastfeed (two cases and 14 controls) were included in the reference category. 
‘Current users’ of OCs were defined as those who were currently using OCs during the 
index-year and started at least 1 year before symptom onset. A total of four cases and seven 
controls had started using OCs during the index-year and they were excluded from the 
analyses. ‘Past users’ were defined as those who used OCs in the past and had stopped at 
least the year before the index-year. ‘Ever users’ were defined as current and past users while 
‘never users’ included women who had not used OCs before the index-year.  
3.3.3 Menopausal factors 
In both cohorts, participants were asked as part of each questionnaire (until 2002 in NHS) 
whether their menstrual periods had ceased permanently and, if so, at what age and the type 
of menopause they had experienced (natural, radiation-induced, or surgical). Menopausal 
status was categorized into premenopausal, postmenopausal or unclear. Age at menopause 
was categorized as ≤44 years, 45-49 years, ≥50 years. We further stratified type of 
menopause at different ages into the following categories: natural ≤44 years, natural ≥45 
years, surgical ≤44 years, surgical ≥45 years, and missing. Finally, after excluding women 
who had undergone hysterectomy and removal of one ovary (as their age at menopause is 
unknown), we calculated total ovulatory years as the age at natural menopause or age at 
surgical menopause (if both ovaries were removed), subtracting the age at menarche, number 
of children born (12 months each), and years of OC use. Ovulatory years were then 
categorized as <24 years, 24-29 years, 30-34 years, ≥35 years, and missing.  
In each cohort, information on PMH use was collected at baseline and at each biennial 
questionnaire. In the analyses of PMH, we investigated never/past/current PMH use, age at 
initiation (never, ≤44 years, 45-49 years, ≥50 years, and missing), and total duration of PMH 
use (never, <4 years, 4 to ≤8 years, ≥8 years, missing). We analyzed PMH use only among 
postmenopausal women. 
3.3.4 PMH 
The questions regarding PMH use included the type of medication and the time (years) of 
initiation and end of the therapy. Medications were later coded according to the Anatomical 
Therapeutic Chemical (ATC) classification system [84] and classified as estrogen alone or a 
combination of estrogen plus progestogen. The latter group represents a broad classification 
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including the natural hormone, progesterone, and the synthetic form, progestin and included 
both combined and sequential regimens. 
 
3.4 CONFOUNDING FACTORS 
For all of the studies including EIRA data (Papers I, II and IV) we adjusted for the matching 
variables (age and residential area). Although sex is an important matching variable in EIRA, 
we did not include it as all of our analyses were restricted to women. We performed 
additional adjustments for potential confounders for each one of the four studies, as follows: 
Cigarette smoking, BMI, level of education (university degree yes/no), BF and OC use for all 
studies including EIRA material (Papers I, II and IV); parity, number of children, age at 
menarche, age at first birth and post-partum period for papers II and IV; and menopausal 
status, PMH and alcohol consumption for Paper II. Of these, only pack-years of cigarette 
smoking (0 to <10, ≥10 to <20 and ≥20) affected the estimates and were included in adjusted 
models. 
For the NHS (Paper III), hazard ratios (HRs) were adjusted in a multivariate analysis for age 
(updated at each cycle of the NHS questionnaire), questionnaire cycle, median household 
income in quintiles, BMI, pack-years of cigarette smoking, and parity/BF (nulliparous, none 
to <1 month, 1-11 months, and ≥12 months). Additional variables, including alcohol 
consumption, OC use, age at menarche, and irregular menses, were considered as potential 
confounders, but because they did not substantially alter the hazard ratio estimates they were 
not included in the final models. 
3.5 STATISTICAL ANALYSIS 
Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for ACPA-positive 
and ACPA-negative RA, by means of unconditional logistic regression for all studies 
including EIRA material (Papers I, II and IV). We conducted both unmatched and matched 
analyses (unconditional/conditional logistic regression) but only presented unconditional 
results as they were in close agreement with the conditional analyses, but had a higher 
precision. All analyses were carried out using the Statistical Analysis System (SAS). 
3.5.1 Paper I 
Parous women were compared with nulliparous in different age groups. We also investigated 
the effect of number of children, age at first birth and postpartum period on RA risk.  
3.5.2 Paper II 
Total lifetime duration of BF for 7-12 and ≥13 months were compared with the shortest 
duration of BF (0-6 months).  
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We also explored the effect of BF according to number of children breastfed (one, two and 
three or more).  With regard to OC use, current/past/ever users were compared with never 
users. A short (≤7 years) or long (>7 years) duration of OC use was compared with no use at 
all (never OC users). 
3.5.3 Paper III 
The relative risks of three outcomes, seropositive, seronegative and overall RA, were 
analyzed by calculating the incidence rate ratios in different age-groups compared with 
women aged 25-44 years. 
Cox proportional hazards models were used to obtain HRs with 95% CIs of seropositive or 
seronegative RA associated with each factor in separate models including menopausal status, 
age at menopause, type of menopause, and ovulatory years. We censored women at first self-
report of cancer, RA, or other connective tissue disease if not confirmed as RA, as well as RA 
diagnosis or death, whichever came first. Premenopausal women were considered as the 
reference group, except in the analysis of ovulatory years (reference group: <24 years).  
We further analyzed risk of RA according to PMH among only postmenopausal women in 
separate models including current/past PMH use, age at initiation and duration of PMH, with 
never users as the reference category. The analyses were performed separately for NHS and 
NHSII and pooled by meta-analysis using the random effects methods of DerSimonian and 
Laird. [85] Two-sided p-values <0.05 were considered statistically significant. All analyses 
were performed using SAS version 9.3. 
3.5.4 Paper IV 
Current, past and ever PMH users were compared with never users. We also analyzed 
different age groups, duration of PMH use (1-6 and ≥7 years) and type of preparation. 
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Table 3. Overview of pepers included in this thesis 
Paper I II III IV 
Short title Parity and risk of RA BF, OC and risk of RA Menopausal factors and risk 
of RA 
PMH and risk of RA 
Study design Case-control Case-control Cohort Case-control 
Study 
population 
2035 cases, 2911 
controls. Women aged 
18-70 years, living in 
Sweden, between 1996 
and 2009 
2641 cases, 4251 controls, between 
1996 and 2014 (OC use).  884 cases, 
1949 controls, between 2006 and 
2014 (BF) 
1,096 incident RA cases. 
In NHS 120,700 female nurses 
aged 30-55 (1976-2010) and in 
NHSII 116,430 female nurses 
aged 25-42 (1989-2011) were 
followed 
523 cases, 1057 controls.  
Women aged 50-70 years, 
living in Sweden, between 2006 
and 2011  
Main 
exposures 
Parity, postpartum 
period, age at first birth 
BF (time in months), oral 
contraceptive use (duration) 
Menopausal factors 
(menopausal status, age at 
menopause, type of menopause, 
ovulatory years and PMH use) 
Postmenopausal hormone 
therapy (type of therapy and 
duration) 
Main outcome ACPA+/- RA ACPA+/- RA Seropositive/seronegative RA ACPA+/- RA 
Potential 
confounders 
Matching variables (age 
and residential area). 
Additional adjustments: 
smoking (pack-years), 
BMI, oral contraceptive 
use, breastfeeding and 
university degree 
Matching variables (age and 
residential area) and smoking (pack-
years). Additional adjustments: 
parity, number of children,  BMI, 
menopausal status, PMH use, age at 
menarche, age at first birth, 
postpartum period, alcohol 
consumption and university degree. 
 
Age, questionnaire cycle, 
median household income in 
quintiles, BMI, smoking (pack-
years), parity/BF, alcohol 
consumption, oral contraceptive 
use, age at menarche, and 
irregular menses 
Matching variables (age and 
residential area) and smoking 
(pack-years). Additional 
adjustments: parity, number of 
children,  BMI, OC use, BF, 
age at menarche, age at first 
birth, postpartum period, and 
university degree 
Statistical 
method 
Logistic regression Logistic regression Cox proportional hazards 
models 
Logistic regression 
RA=rheumatoid arthritis, BF=breastfeeding, OC= oral contraceptive, PMH=postmenopausal hormone therapy, ACPA=anti-citrullinated protein 
antibody, BMI=body mass index, NHS=Nurses’ Health Study, NHSII=second cohort of the NHS.
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4 RESULTS 
A concise overview of the most important findings of this thesis will be provided in this 
section. For further details, please see the individual publications included at the end of the 
thesis. 
 
4.1 PARITY AND THE RISK OF RA (PAPER I) 
In total, 2035 cases and 2911 controls were included in the analyses; of these, 603 cases and 
906 controls were aged 18-44 years. In all, 64% of cases were ACPA-positive and the mean 
time period between symptom onset and diagnosis was 10 months for both ACPA-positive 
and ACPA-negative RA cases. 
4.1.1 Parity and the risk of ACPA-positive/-negative RA 
Parous women had an increased risk of developing ACPA-negative RA compared with 
nulliparous women in the younger age-group (18-44 years) (OR=2.1, 95% CI 1.4-3.2), but 
not in the older age-group (45-70) (OR=0.9, 95% CI 0.7-1.3). There was no association 
between parity and the risk of developing ACPA-positive RA in either age-group (Table 4) 
nor were there any differences in the risk of ACPA-positive and ACPA-negative RA 
according to the number of children. 
 
Table 4. Relative risk of ACPA-positive and ACPA-negative RA according to parity, in 
different age-groups. EIRA, Sweden, 1996-2006 
  18-44 years 45-70 years 
ACPA status Parous Cases/Controls OR
a
 95% CI Cases/Controls OR
a
 95% CI 
ACPA-
positive 
No 165/360 1.0 112/238 1.0 
Yes 237/546 0.9 (0.7-1.2) 797/1766 1.0 (0.8-1.2) 
 
ACPA-
negative 
No 65/360 1.0 65/238 1.0 
Yes 136/546 2.1 (1.4-3.2) 458/1766 0.9 (0.7-1.3) 
 
RA overall No 230/360 1.0 177/238 1.0 
 Yes  373/546 1.1 (0.9-1.5) 1255/1766 1.0 (0.8-1.2) 
ACPA= anti-citrullinated protein antibodies, RA= rheumatoid arthritis, OR= odds ratio, CI= 
confidence interval, EIRA=Epidemiological Investigation of Rheumatoid Arthritis.  
a
 Adjusted for matching variables (age and residential area).  
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4.1.2 Postpartum period and risk of ACPA-positive/-negative RA 
An increased risk of ACPA-negative RA was found in women, aged 18-44 years, who had 
their last child the same year as the index-year (OR=2.6, 95% CI 1.4-4.8). The OR was lower 
among those whose last child was born within 1 year before the index-year (OR=1.8, 95% CI 
0.9-3.6) and reached the null value within 2 years before disease onset (Table 5). The 
estimates decreased after adjustment for age at first birth.  
 
Table 5. Relative risk of ACPA-positive and ACPA-negative RA according to 
postpartum period for the last delivered child in women aged 18-44 years. EIRA, 
Sweden, 1996-2006 
ACPA 
status 
Years between last 
delivered child and 
index-year 
Cases/Controls OR
a
 95% CI OR
b
 95% CI 
ACPA-
positive 
 
Nulliparous 165/360 1.0 1.0 
0 29/59 1.1 (0.7-1.8) 0.8 (0.4-1.6) 
1 year 27/57 1.1 (0.6-1.8) 0.8 (0.4-1.5) 
2 years 20/49 0.9 (0.5-1.5) 0.6 (0.3-1.3) 
 p for trend
 c
 - 0.9136 0.6316 
     
ACPA-
negative 
Nulliparous 65/360 1.0 1.0 
0 23/59 2.6 (1.4-4.8) 2.1 (0.9-4.8) 
 1 year 14/57 1.8 (0.9-3.6) 1.4 (0.6-3.6) 
 2 years 6/49 1.0 (0.4-2.5) 0.8 (0.2-2.3) 
 p for trend
 c
 - 0.0093 0.1336 
ACPA= anti-citrullinated protein antibodies, RA= rheumatoid arthritis,  
OR= odds ratio, EIRA=Epidemiological Investigation of Rheumatoid Arthritis.
 
a
 Adjusted for matching variables (age and residential area). 
b
 Adjusted for age, residential area and age at first birth. 
c
 Wald chi-squared test for trend. 
 
4.1.3 Age at first birth and risk of ACPA-positive/-negative RA 
Among women aged 18-44 years who had their first child before 23 years of age the OR of 
ACPA-negative RA was 2.5 (95% CI 1.5-4.1). The OR decreased by increasing age at first 
birth. A moderately decreased risk of ACPA-positive RA was found among women who had 
their first child after 30 years of age (OR=0.7, 95% CI 0.4-1.0) Adjustment for the 
postpartum period increased the risk estimates for ACPA-negative RA, and decreased the 
estimates for ACPA-positive RA. 
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4.2 BF, OC USE AND THE RISK OF RA (PAPER II) 
In total, 2637 cases and 4244 controls were included in the analyses. In all, 1753 (66.5%) 
cases were ACPA-positive and the mean time period between symptom onset and diagnosis 
was 10 months for both serological phenotypes of RA. 
4.2.1 BF and the risk of RA 
Compared with women who breastfed for 0-6 months, those who breastfed their children for 
7-12 months had an OR of 0.93 (95% CI 0.75-1.14) of developing RA, while BF for 13 
months or more significantly reduced the risk of RA (OR=0.77, 95% CI 0.63-0.94). The trend 
was significant for ACPA-positive, but not for ACPA-negative RA. These estimates were 
attenuated after adjustment for pack-years of smoking (Table 6).  
 
Table 6.  Relative risk of ACPA-positive, ACPA-negative and RA overall according to 
breastfeeding. EIRA, Sweden, 2006-2014 
ACPA-status Breastfeeding Cases/Controls OR (95% CI)
a
 OR (95% CI)
b
 
ACPA-
positive 
≤6 months 194/533 1.0 1.0 
7-12 months 192/574 0.91 (0.72-1.15) 0.99 (0.78-1.26) 
≥13 months 234/842 0.74 (0.59-0.93) 0.88 (0.70-1.11) 
p-value trend - 0.0086 0.2644 
 
ACPA-
negative 
≤6 months 81/533 1.0 1.0 
7-12 months 83/574 0.97 (0.70-1.35) 1.02 (0.73-1.43) 
≥13 months 100/842 0.83 (0.60-1.15) 0.92 (0.66-1.28) 
p-value trend - 0.2405 0.5951 
 
RA overall ≤6 months 275/533 1.0 1.0 
 7-12 months 275/574 0.93 (0.75-1.14) 0.99 (0.80-1.22) 
 ≥13 months 334/842 0.77 (0.63-0.94) 0.89 (0.72-1.09) 
 p-value trend - 0.0075 0.2366 
a
 Adjusted for age and residential area 
b
 Adjusted for age, residential area and smoking (pack-years) 
ACPA= anti-citrullinated protein antibodies, RA= rheumatoid arthritis, OR= odds ratio, CI= 
confidence interval, EIRA=Epidemiological Investigation of Rheumatoid Arthritis. 
 
4.2.2 RA risk according to number of children breastfed 
Among women who only breastfed one child, we observed a non-significant decreased risk 
of developing RA overall (OR=0.86, 95% CI 0.57-1.29), and especially of ACPA-negative 
RA.  
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This decrease in risk was not as large among women who breastfed a total of two children 
(OR=0.91, 95% CI 0.71-1.71), almost reaching the null value among those who breastfed 
three or more children (OR=1.08, 95% CI 0.78-1.49). 
4.2.3 OC use and the risk of RA 
Ever users of OCs had a decreased risk of developing RA compared with never users 
(OR=0.88, 95% CI 0.79-0.98). The ORs were 0.86 (95% CI 0.69-1.07) and 0.88 (95% CI 
0.80-0.98) for current and past users respectively. The association between ever and past OC 
use was significant for ACPA-positive but not for ACPA-negative RA. The estimates for ever 
and past OC use remained significant after adjustment for smoking (pack-years) (Table 7).  
A longer duration of ever OC use (>7 years) was significantly associated with a decreased 
risk of RA overall (OR=0.83, 95% CI 0.73-0.94) and ACPA-positive RA (OR=0.82, 95% CI 
0.71-0.95), while a non-significant association was found for ACPA-negative RA (OR=0.83, 
95% CI 0.69-1.01). 
 
Table 7. Relative risk of ACPA-positive, ACPA-negative and RA overall according to oral 
contraceptive use among women. EIRA, Sweden, 1996-2014 
ACPA status OC use Cases/Controls OR 95% CI
a
 OR 95% CI
b
 
ACPA-positive Ever 1135/2862 0.85 (0.75-0.96) 0.81 (0.71-0.92) 
   Current 134/331 0.87 (0.68-1.12) 0.85 (0.66-1.10) 
   Past 1001/2531 0.85 (0.75-.096) 0.80 (0.70-0.91) 
Never 572/1267 1.0 1.0 
Missing 46/115 - - 
ACPA-negative Ever 582/2862 0.94 (0.80-1.11) 0.91 (0.77-1.07) 
   Current 61/331 0.83 (0.59-1.17) 0.78 (0.55-1.11) 
   Past 521/2531 0.95 (0.81-1.12) 0.92 (0.78-1.09) 
Never 289/1267 1.0 1.0 
Missing 13/115 - - 
RA overall Ever 1717/2862 0.88 (0.79-0.98) 0.84 (0.75-0.94) 
   Current 195/331 0.86 (0.69-1.07) 0.83 (0.67-1.04) 
   Past 1522/2531 0.88 (0.80-0.98) 0.84 (0.75-0.94) 
Never 861/1267 1.0 1.0 
Missing 59/115 - - 
a
 Adjusted for age and residential area 
b
 Adjusted for age, residential area and smoking (pack-years) 
ACPA= anti-citrullinated protein antibodies, RA= rheumatoid arthritis, OC= oral 
contraceptives, OR= odds ratio, CI= confidence interval, EIRA=Epidemiological 
Investigation of Rheumatoid Arthritis. 
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4.3 MENOPAUSAL FACTORS AND THE RISK OF RA (PAPER III) 
The study population for Paper III was 109,443 women contributing 2,498,323 person-years 
in NHS from 1976-2010, and 112,523 women contributing 1,987,756 person-years in NHSII 
from 1989-2011. A total of 1,096 cases were included in the analyses (729 in NHS, 367 in 
NHSII; 401 seronegative/695 seropositive cases). 
4.3.1 Age and risk of RA 
Women aged 45 years or older had an increased risk of RA in all age-groups, compared with 
women aged 25-44 years, with peak HR at 55-59 years. For all RA, the pooled HRs were 1.5 
(95% CI 1.2-1.9) at ages 45-49 years, 2.0 (95% CI 1.6-2.5) at ages 50-54 years, 2.3 (95% CI 
1.7-3.2) at ages 55-59 years and 1.9 (95% CI 1.4-2.6) at ages 60-64 years. There were no 
large differences between NHS and NHSII; however there were very few cases aged 60 years 
or greater in NHSII. For seronegative RA, the pattern was similar, with a peak HR at ages 55-
59 in the pooled analysis. Women aged 50 or more had an increased risk of seropositive RA, 
with peak HR at ages 55-59. 
4.3.2 Menopausal factors and risk of seropositive/seronegative RA 
Postmenopausal women had an increased risk of seronegative RA, compared with 
premenopausal women, in a multivariate analysis (pooled HR=2.1, 95% CI 1.4-3.0) (Table 
8). Any age at menopause was associated with an increased risk of seronegative RA, with the 
highest HR observed among women with natural menopause at early age (<45 years) (pooled 
HR=2.4, 95% CI 1.5-4.0). Longer duration of ovulatory years appeared to be associated with 
a decreased risk, at least in NHSII. None of the menopausal factors were significantly 
associated with seropositive RA (for postmenopausal women compared with premenopausal 
women, pooled HR=1.2, 95% CI 0.9-1.6). 
4.3.3 PMH use and risk of seropositive/seronegative RA 
Current PMH use was modestly associated with a non-significantly increased risk of 
seronegative RA (pooled HR=1.3, 95% CI 0.9-1.8), while there was no association with past 
PMH use. Long duration of PMH use (≥8 years) was related to a non-significantly increased 
risk of seronegative RA (pooled HR=1.4, 95% CI 1.0-2.0), but age at PMH initiation or time 
since last use were not associated with this sub-group of disease. 
Regarding seropositive RA, current PMH users had an increased risk only in NHS (HR=1.4, 
95% CI 1.1-1.9), but not in NHSII (HR=0.9, 95% CI 0.5-1.7) with a pooled HR of 1.3 (95% 
CI 0.9-1.8). There was no association with past PMH use in either cohort.  Long duration of 
PMH use (≥8 years) was significantly associated with risk of seropositive RA (pooled 
HR=1.4, 95% CI 1.1-1.9). However, age at initiation of PMH was not associated with either 
type of RA.  
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Table 8. Menopausal status and the relative risk of seropositive RA and seronegative RA in the NHS (1976-2010) and 
NHSII (1989-2011) cohorts 
 Seronegative RA 
 NHS NHSII Pooled 
(NHS+NHSII) 
Factors Cases Person-years HR 95%CI
1
 Cases Person-years HR 95%CI
1
 HR 95%CI
1
 
Menopausal status        
    Pre-menopausal 52 755,275 1.0 71 1479200 1.0 1.0 
    Postmenopausal 201 1,600,561 1.8 (1.1-3.0) 53 423261 2.4 (1.4-3.9) 2.1 (1.4-3.0)     
    Unclear
b
 16 130,556 1.5 (0.8-2.9) 8 80277 2.1 (1.0-4.8) 1.7 (1.0-2.9)      
Type of menopause        
    Pre-menopausal 52 755,275 1.0 71 1479200 1.0 1.0 
    Natural 165 1,281,514 2.0 (1.2-3.4) 30 281384 1.9 (1.0-3.6) 2.0 (1.3-2.9) 
    Surgical 36 319,046 1.6 (0.9-2.8) 23 141876 2.7 (1.6-4.7)     2.1 (1.2-3.5) 
Age at menopause        
    Pre-menopausal 52 755,275 1.0 71 1479200 1.0 1.0 
    ≤ 44 years     33 223,806 1.9 (1.1-3.2) 18 132428 2.4 (1.3-4.2) 2.1 (1.4-3.1) 
    45-49 years 55 412,947 1.7 (1.0-3.0) 11 125915 1.8 (0.8-3.8) 1.7 (1.1-2.7) 
    ≥ 50 years 77 658,661 1.7 (1.0-2.9) 18 138738 2.7 (1.2-6.1)  2.0 (1.2-3.1) 
Type of/age at menopause       
   Pre-menopausal 52 755,275 1.0 71 1,479,200 1.0 1.0 
   Natural≤44 15 74.935 2.7 (1.4-5.3) 6 41,718 2.6 (1.1-6.2) 2.4 (1.5-4.0)      
   Natural≥45 116 919,120 1.8 (1.1-3.1) 23 222,463 2.0 (1.0-4.0) 1.8 (1.2-2.8) 
   Surgical≤44 18 148,871 1.6 (0.8-2.9) 12 90,711 2.2 (1.1-4.2) 1.8 (1.0-3.0)      
   Surgical≥45 16 152,488 1.4 (0.7-2.8) 6 42,190 2.6 (1.0-6.8) 1.6 (0.9-2.9) 
Ovulatory years        
   < 24 years 42 465,671 1.0 25 505367 1.0 1.0 
   24-29 years 53 518,520 0.9 (0.6-1.4) 27 545347 0.4 (0.2-0.8) 0.6 (0.2-1.5)        
   30-34 years 57 589,439 0.7 (0.5-1.1) 35 415482 0.4 (0.1-0.9) 0.6 (0.3-1.1)     
   ≥ 35 years 47 412,547 0.8 (0.5-1.3) 21 228713 0.4 (0.1-1.1) 0.7 (0.3-1.3)        
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 Seropositive RA 
 NHS NHSII Pooled 
(NHS+NHSII) 
Factors Cases Person-years HR 95%CI
1
 Cases Person-years HR 95%CI
1
 HR 95%CI
1
 
Menopausal status        
    Pre-menopausal 101 750,055 1.0 141 1,447,465 1.0 1.0 
    Postmenopausal 327 1,594,188 1.3 (0.9-1.9) 83 417,058 1.1 (0.7-1.7) 1.2 (0.9-1.6)        
    Unclear
b
 32 129,495 1.3 (0.8-2.1) 11 78,782 0.8 (0.4-1.6) 1.3 (0.9-1.8)        
Type of menopause        
    Pre-menopausal 101 750,055 1.0 141 1,447,465 1.0 1.0 
    Natural 265 1,277,316 1.3 (0.9-2.0) 53 278,836 1.0 (0.6-1.6) 1.2 (0.9-1.6)        
    Surgical 62 316,872 1.3 (0.8-1.9) 30 138,222 1.3 (0.8-2.0) 1.3 (0.9-1.7)        
Age at menopause        
    Pre-menopausal 101 750,055 1.0 141 1,447,465 1.0 1.0 
    ≤ 44 years     51 222,262 1.4 (0.9-2.1) 19 128,843 0.9 (0.6-1.6) 1.2 (0.9-1.7)        
    45-49 years 87 411,303 1.2 (0.8-1.9) 26 124,646 1.1 (0.7-1.9) 1.2 (0.9-1.7)        
    ≥ 50 years 126 656,583 1.2 (0.8-1.9) 30 137,833 1.1 (0.6-2.0) 1.2 (0.9-1.7)        
Type of/age at 
menopause 
       
   Pre-menopausal 101 750,055 1.0 141 1,447,465 1.0 1.0 
   Natural≤44 21 74,559 1.6 (1.0-2.8) 5 40,939 0.8 (0.3-1.9) 1.4 (0.9-2.3)        
   Natural≥45 184 916,366 1.3 (0.8-1.9) 44 220,848 1.0 (0.6-1.7) 1.1 (0.8-1.6)        
   Surgical≤44 30 147,703 1.2 (0.8-2.0) 14 87,904 1.0 (0.6-1.8) 1.1 (0.8-1.7)        
   Surgical≥45 29 151,519 1.3 (0.8-2.1) 12 41,631 1.6 (0.8-3.1) 1.4 (0.9-2.1) 
Ovulatory years        
   < 24 years 67 462,049 1.0 34 493,200 1.0 1.0 
   24-29 years 88 516,119 0.9 (0.6-1.3) 51 531,987 1.1 (0.6-2.2) 1.1 (0.8-1.5)        
   30-34 years 121 586,979 1.0 (0.7-1.4) 62 408,867 1.5 (0.7-3.3) 1.1 (0.8-1.5)        
   ≥ 35 years 75 410,846 0.9 (0.6-1.3) 42 226,651 1.4 (0.6-3.2) 1.2 (0.8-1.7)        
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Footnote for Table 8: 
a
Cox proportional hazards models adjusted for age, questionnaire cycle, median household 
income, BMI, smoking pack-years, breastfeeding, parity. Reference category is 
premenopausal women for menopausal variables. 
b
Unclear includes women whose date of menopause is unclear due to hysterectomy with 
unilateral oophorectomy, or menopause due to radiation. 
Missings values for each model (cases/person years):  
Seronegative, Type of menopause: NHS 16/130,556, NHSII 8/80,277; Age at menopause: 
NHS 52/435,703, NHSII 14/106,456; Type of/age at menopause: NHS 52/435,703 NHSII 
14/106,456; Ovulatory years: NHS 70/500,215 NHSII 24/287,830. 
Seropositive, Type of menopause: NHS 32/129,495 NHSII 11/78,782; Age at menopause: 
NHS 95/433,535 NHSII 19/104,518; Type of/age at menopause: NHS 95/433,535 NHSII 
19/104,518; Ovulatory years: NHS 109/497,745 NHSII 46/282,600. 
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4.4 PMH AND THE RISK OF RA (PAPER IV) 
In total, 467 cases and 935 controls were included in the analyses. In all, 303 (64.9%) cases 
were ACPA-positive and the mean duration of disease at inclusion in the study was 10 
months for both ACPA-positive and ACPA-negative RA. Cases were more likely to be ever 
smokers, overweight, and to have a lower level of education. 
4.4.1 Current/past use of PMH and risk of RA 
Compared with never users, current users of PMH had a decreased risk of developing ACPA-
positive RA (OR=0.6, 95% CI 0.3-0.9) in the adjusted model, but no association was 
observed for past users. No association was found between ever, current or past use of PMH 
and the risk of ACPA-negative RA (Table 9).  
 
Table 9. Relative risk of ACPA-positive, ACPA-negative and RA overall according to ever, 
current and past use of PMH among women aged 50-70 years. EIRA, Sweden, 2006-2011 
ACPA status Use of PMH Cases/Controls  OR 95% CI
a
 OR 95% CI
b
 
ACPA-positive Ever
c
 90/304 0.9 (0.7-1.2) 0.9 (0.6-1.2) 
 Current 22/105 0.6 (0.4-1.0) 0.6 (0.3-0.9) 
 Past 68/197 1.0 (0.7-1.4) 1.1 (0.8-1.5) 
 Never 209/626 1.0 1.0 
 Missing
d
 4/5 - - 
 
ACPA-negative Ever 55/304 1.1 (0.7-1.5) 1.0 (0.7-1.4) 
 Current 18/105 1.0 (0.6-1.7) 0.9 (0.5-1.5) 
 Past 37/197 1.1 (0.7-1.7) 1.1 (0.7-1.7) 
 Never 109/626 1.0 1.0 
 Missing§ 0/5 - - 
 
RA overall Ever 145/304 0.9 (0.7-1.2) 0.9 (0.7-1.2) 
 Current 40/105 0.7 (0.5-1.1) 0.7 (0.4-1.0) 
 Past 105/197 1.1 (0.8-1.4) 1.1 (0.8-1.4) 
 Never 318/626 1.0 1.0 
 Missing
d
 4/5 - - 
a
 Adjusted for age and residential area. 
b
 Adjusted for age, residential area and smoking (pack-years). 
c
 Two controls only had information on year of initiation and type of therapy and were 
defined as ever users.  
d
 Missing information on PMH use. 
ACPA= anti-citrullinated protein antibodies, PMH= postmenopausal hormone, RA= 
rheumatoid arthritis, OR= odds ratio, CI= confidence interval, EIRA=Epidemiological 
Investigation of Rheumatoid Arthritis. 
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4.4.2 Duration of PMH and risk of RA 
A shorter duration of PMH (1-6 years) was associated with a decreased risk of ACPA-
positive RA among current users (adjusted OR=0.3, 95% CI 0.1-0.7). The association was 
not statistically significant for ACPA-negative RA (adjusted OR=0.4, 95% CI 0.1-1.3). A 
longer duration of PMH among current as well as past users was not associated with ACPA-
positive RA. A longer duration was associated with a non-significantly increased risk of 
ACPA-negative RA among current (OR=1.3, 95% CI 0.7-2.4) but not among past PMH users 
(OR=0.9, 95% CI 0.5-1.7).  
4.4.3 Current/past use of PMH and risk of RA in different age groups 
The decreased risk of ACPA-positive RA among current users of PMH was observed mainly 
in the group of women aged 50-59 years (OR=0.3, 95% CI 0.1-0.8), while no significant 
effect was observed in those aged 60-70 years (OR=0.8, 95% CI 0.4-1.4). No association 
between past PMH use and the risk of ACPA-positive RA was observed. No association 
between past/current PMH use and risk of ACPA-negative RA was observed in any of the 
age groups.  
4.4.4 Type of therapy and risk of RA 
Among current users of a combined PMH therapy (estrogen plus progestogens) an OR of 0.3 
(95% CI 0.1-0.7) of developing ACPA-positive RA was observed. There was no significant 
association between current PMH use and ACPA-positive RA among women who used 
estrogen alone (OR=0.8, 95% CI 0.5-1.6). For the ACPA-negative subset, no association was 
found for ever, current, or past use of either type of PMH therapy (Table 10).  
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Table 10. Relative risk of ACPA-positive and ACPA-negative RA according to type of 
medication, among women aged 50-70 years. EIRA, Sweden, 2006-2011 
  Estrogen only  Estrogen + progestogens
a
 
ACPA status Use of 
PMH 
 
Cases/Controls 
 
OR 95% CI
b
 
  
Cases/Controls 
 
OR 95% CI
b
 
ACPA-
positive  
Ever 57/165 1.1 (0.7-1.5)  33/139 0.7 (0.5-1.1) 
   Current 15/50 0.8 (0.5-1.6)  7/55 0.3 (0.1-0.7) 
   Past 42/114 1.2 (0.8-1.8)  26/83 1.0 (0.6-1.6) 
Never 209/626 1.0  209/626 1.0 
Missing 4/5 -  4/5 - 
ACPA-
negative  
Ever 31/165 1.0 (0.7-1.6)  24/139 1.0 (0.6-1.6) 
   Current 9/50 0.8 (0.3-1.8)  9/55 0.9 (0.4-2.0) 
   Past 22/114 1.1 (0.7-1.9)  15/83 1.1 (0.6-2.0) 
Never 109/626 1.0  109/626 1.0 
Missing 0/5 -  0/5 - 
a
 The estrogen plus progestogen group includes both combined and sequential regimens. 
b
 Adjusted by age, residential area and smoking (pack-years). 
ACPA= anti-citrullinated protein antibodies, RA= rheumatoid arthritis, PMH= 
postmenopausal hormone therapy, OR= odds ratio, CI= confidence interval, 
EIRA=Epidemiological Investigation of Rheumatoid Arthritis. 
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Table 11. Summary of main results obtained and presented in this thesis 
Paper Specific results Seropositive 
RA 
Seronegative 
RA 
Parity and 
risk of RA 
(Paper I) 
Parity among young women (18-44 
years) 
NA ↑ 
Postpartum period NA ↑ 
Young age at first age NA ↑ 
BF, OC and 
risk of RA 
(Paper II) 
BF ≥13 months (among parous women) ↓ NA 
Ever OC use ↓ NA 
    Current OC use NA NA 
    Past OC use ↓ NA 
Long duration (≥8y) among ever and 
past OC users 
↓ ↓ 
Menopausal 
factors and 
risk of RA 
(Paper III) 
Older age ↑ ↑ 
Postmenopausal women compared with 
premenopausal 
NA ↑ 
Natural menopause at early age (≤44 
years) 
NA ↑ 
Long duration of PMH (≥8y) ↑ ↑ 
    
PMH and risk 
of RA (Paper 
IV) 
Current PMH use among women aged 
50-70 years  
↓ NA 
Current PMH use among women aged 
50-59 years 
↓ NA 
Shorter duration of PMH use ↓ NA 
Use of a combined PMH therapy 
(estrogen plus progestogens) 
↓ NA 
↑= increased risk, ↓= decreased risk, NA= No association 
BF= breastfeeding, OC= oral contraceptive, PMH= postmenopausal hormone therapy 
Results from Papers I, II and IV are specific for ACPA-status, while results from Paper III are 
for either RF or ACPA.  
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5 DISCUSSION 
5.1 COMMENTS ON PRESENT RESULTS AND PREVIOUS STUDIES 
5.1.1 Parity and the risk of RA (Paper I) 
Our results have shown that parous women of reproductive age (18-44 years) had an 
increased risk of ACPA-negative RA.  We found an elevated risk during the postpartum 
period, and among women who had a young age at first birth. We found no association 
between either parity or the postpartum period and the risk of ACPA-positive RA, but older 
age at first birth appeared to be associated with a decreased risk of this RA subset. 
In general, parity has previously been described as a risk factor for RA close to delivery [39-
42] but after some years this risk might weaken [43-49]. Our results provide more detailed 
information, showing that the increased postpartum risk is restricted to ACPA-negative RA. 
Inconsistent findings with regard to other factors, such as age at first birth and number of 
children, might be due to methodological issues, such as inclusion of prevalent cases, [49] 
inclusion of non-population-based controls [48, 49] or relatively few cases [45-49]. The 
decreased risk of ACPA-negative RA with increasing age remained even after adjustments 
for potential confounders. 
Pregnancy entails considerable immunological adaptation. The high concentrations of various 
circulating hormones (e.g. cortisol, estrogen) (Figure 2), might account for the lower RA 
incidence in the months of pregnancy. [86] The considerable drop in hormonal levels after 
delivery together with high prolactin levels during BF might explain the increased postpartum 
RA risk. [87]  
Figure 2. Hormone changes in week of hormones important for the regulation of gestation in 
healthy pregnant women. CRH= corticotropin releasing hormone, hCG= human chorionic 
gonadotropin. [88] 
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5.1.2 BF, OCs and the risk of RA (Paper II) 
We found a decreased risk of developing ACPA-positive RA among parous women who 
breastfed more than 1 year, compared with parous women who breastfed for up to 6 months. 
This decreased risk was non-significant after adjustment for smoking. Women who had 
breastfed one child had a lower risk of RA, and especially ACPA-negative RA, compared 
with women who had breastfed three or more children. Ever and past use of OCs was 
significantly associated with a decreased risk of developing ACPA-positive RA. The decrease 
in risk was greater for a longer duration of use. 
From reviewing the literature on the association between BF and RA, it is clear that a 
consensus has not been reached. Some authors have described an increased risk of RA with 
increasing time of BF [51] or mainly related to the first pregnancy. [52] Consistent with our 
results, other studies have found a protective effect of BF. In a large prospective cohort study, 
Karlson et al found a decreased risk of RA among women who breastfed for more than 12 
months, with a significant trend with increased duration of BF. [44] In this study, a similar 
pattern was observed for RF-positive cases. Similar results have been found in Swedish, [46] 
British, [54] and Asian populations, [50] including a recently published systematic review 
and meta-analysis that includes conflicting results. [89] Our results confirm and extend these 
findings by adding the stratification according to ACPA-status, which has not been 
previously explored. 
Most studies investigating OC use and the risk of RA have not been able to prove an 
association [42, 44, 46, 49, 51, 55-59] including two  recently published meta-analyses. [60, 
61] Those that have shown a significant association are in line with our results, [62-67] 
including a report of a protective effect with a longer duration of OC use. [51] A decreased 
risk of RA has been associated with OC use especially in early years when preparations 
contained higher doses of estrogen. [62] Several studies have shown no associations between 
low-dose estrogens and RA. [44, 46, 61] Different methodologies (e.g. study design) as well 
as insufficient sample size might also explain these disparate previous results.  
Prolactin, which is the hormone related to lactation, has been mostly linked with an increased 
risk of RA due to its immunostimulating properties. [90] Recent findings, however, suggest 
that prolactin might act more as a regulator of inflammation, with protective and regenerative 
functions. [91] Other potential biological mechanisms that could explain our results regarding 
BF might be an anti-inflammatory effect given by prolonged effect of progesterone in the 
postpartum period. [92] Finally, elevated levels of cortisol, which has been found to be 
significantly higher among post-menopausal women with a history of BF, might also explain 
our results. [93] The finding of an inverse association between BF and the risk of ACPA-
positive, but not ACPA-negative RA is in line with our results from Paper I, in which we 
observed an increased risk of ACPA-negative but not ACPA-positive RA during the post-
partum period. 
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With regard to our results on OC use and the decreased risk of RA, we found that the 
protective effect was limited to ACPA-positive RA and that a longer duration of OC use had 
a stronger effect, supporting the hypothesis of a dose-response effect.  
Furthermore, these results are in line with our findings from Paper IV (reduced risk of 
developing RA among women who used PMH), demonstrating a similar effect of current use 
of exogenous sex hormones on the risk of RA, but at different stages in life (pre and 
postmenopausal women). Notably, a combined therapy of estrogen and progestogens had the 
strongest protective effect, supporting the hypothesis that progesterone exerts an anti-
inflammatory effect in menopause. 
5.1.3 Menopausal factors and the risk of RA (Paper III) 
Menopausal factors were strongly associated with risk of seronegative, but not seropositive 
RA in these large prospective cohorts. Postmenopausal women had more than a two-fold 
increased risk of seronegative disease, compared with premenopausal women. Those in 
whom a natural menopause occurred at an early age (≤44 years of age) had an HR of 2.4 of 
seronegative RA. We observed no associations between PMH use and the risk of either 
serological phenotype of RA, except for an increased risk of seropositive RA among women 
with a long duration of PMH. Moreover, the peak risk of developing RA was observed at 
ages 55-59 years for both serological phenotypes, which is after the menopausal transition in 
most women.   
To our knowledge, this is the first study to demonstrate that menopausal factors are mainly 
associated with seronegative RA. Menopausal transition is a dynamic process, which can 
occur at different ages among women [94] (Figure 3).  
Figure 3. Stages of reproductive aging. *Stages most likely to be characterized by vasomotor 
symptoms; FSH, follicle stimulating hormone; ↑, elevated; amen., amenorrhea. [94] 
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The menopausal transition and the underlying hormonal changes have been related to an 
increased risk of RA, although the literature has been scarce. [68, 69] Our findings suggest 
that postmenopausal women and those with an early natural menopause are at increased risk 
of RA, but that this risk is restricted to the seronegative phenotype.  
It remains unclear whether the menopausal RA risk is increased due to falling estrogen or 
progesterone levels, but the immunomodulatory effect given by progesterone [95-98] 
together with its anti-inflammatory effect during pregnancy [99] might exert an analogous 
role during the menopausal phase.  
An association between PMH use and the risk of seronegative or seropositive RA could not 
be confirmed in this study. However, the different results observed for NHS and NHSII, 
especially for seropositive RA, are in line with the findings from the EIRA study (Paper IV) 
and might indicate that different strategies over the decades have different impact on disease 
development.  
Apart from one Swedish study in which the RA incidence peaked at 70-79 years of age, [5] 
most previous studies have observed a peak in RA incidence at 45-64 years. [7-9, 100]  In our 
study, we observed that disease incidence peaked later than the mean age at menopause in 
these cohorts (51-52 years), at 55-59 years of age, for both serological RA phenotypes. 
Therefore, menopausal factors might be involved in later development of RA, especially 
seronegative RA, but other factors might promote the peak incidence after menopause. 
Finally, most menopausal factors affected RA risk in a similar way in the two NHS cohorts, 
strengthening the conclusion that these factors are involved in the development of 
seronegative RA. 
5.1.4 PMH and the risk of RA (Paper IV) 
Postmenopausal women who were currently using PMH at onset of their disease had a 
decreased risk of ACPA-positive RA. This decreased risk was mainly observed among 
women aged 50-59 years and only among users of a combined therapy of estrogen and 
progestogens. Women with a short duration of PMH use (≤7 years) also had a decreased risk 
of ACPA-positive RA, which might indicate that the initial time of PMH use has an effect on 
development of ACPA-positive disease.  We were not able to further explore PMH duration 
due to the low number of observations.   
Previous studies on the association between PMH use and the onset of RA have reported 
inconclusive results. [44, 59, 62, 70-76] Our results are in accordance with previous reports 
of a decreased risk of RA among current PMH users [59, 78] and among current users of a 
combined therapy [72] More recently, it has been proposed that the use of hormone 
replacement therapy in women with early undifferentiated arthritis protects against RA in 
individuals carrying HLA-DRB1 SE alleles (OR=0.43, 95% CI 0.24-0.77) by reducing the 
risk for the presence of ACPA. [77] Nevertheless, to the best of our knowledge, our study is 
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the first to investigate this exposure separately by ACPA-status and by type of therapy 
(estrogen only or estrogen plus progestogens).  
One of the most interesting findings from this study was the different result for current users 
of PMH including estrogen alone, compared with users of a combination of estrogens and 
progestogens. This might be explained by the immunomodulatory effect of the natural 
hormone progesterone, which may differ from the effects of estrogens and androgens. [95-98] 
The anti-inflammatory milieu as a result of elevated concentrations of various circulating 
hormones during pregnancy, [86] together with inhibition of T-helper (Th)1 and Th17 
pathways and induction of anti-inflammatory molecules given by progesterone [99] may 
explain the reduced RA incidence during pregnancy. When progesterone levels fall in the 
postpartum period, a higher incidence of RA has been observed; this was confirmed by the 
results of our first study (Paper I), but interestingly confined to ACPA-negative RA.    
Finally, it is important to note that in spite of the protective effect of PMH use found in this 
study, the associations between this therapy and the occurrence of endometrial cancer, breast 
cancer and cardiovascular diseases, among other conditions, should not be ignored. [101, 
102] 
 
5.2 METHODOLOGICAL CONSIDERATIONS 
A number of issues could be considered in this section, but I have chosen to restrict the 
discussion to several topics that in my opinion are the most relevant for this thesis. 
5.2.1 Study design 
We utilized data from two different study designs, namely a case-control and a cohort study. 
A case-control study using incident cases of disease has the advantage of being more cost-
efficient and of obtaining specific exposure information with regard to RA. To our 
knowledge, EIRA is the largest population-based case-control study that has been conducted 
to date, with a substantial number of cases and controls with detailed information on 
environmental/genetic risk factors. By selecting the controls continuously over time, and 
from the same population in which the cases originated, the ORs estimate the rate ratio that 
would be obtained from a cohort study in the same study base. [103] One drawback with this 
study design is its retrospective nature when it comes to exposure assessment. 
The cohort design of the NHS is ideal in terms of obtaining data prior to disease onset from 
the entire source population. The strengths of this design include the repeated and prospective 
assessment of most exposures/confounders, the possibility to adjust for several confounders 
(including BMI, cigarette smoking, alcohol consumption, income, parity and BF) and the 
long follow-up period. Its main weakness is a lower number of incident RA cases, compared 
to the large sample size from a case-control study; the latter is more efficient when studying a 
rare disease such as RA. 
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5.2.2 Selection bias 
The EIRA study has the advantage of being a large, population-based case-control study 
including incident cases of RA. In order to minimize the risk of selection bias that frequently 
threatens the validity of case-control studies, we selected controls randomly and continuously 
from the same study base as the cases. Although the general participation rates have 
decreased over the years (from 95% to 92% among cases and from 81% to 73% among 
controls), we still have a good participation rate when it comes solely to women (95% and 
80% for cases and controls respectively). In addition, the frequency of exposure among 
controls was similar to that in the population.  (e.g. BF habits and PMH use). For example, 
BF among controls was very similar to the high frequency of BF observed in Sweden, [104] 
and we found approximately the same frequency of current PMH use among the controls as 
reported in a previous Swedish study. [105] 
One of the disadvantages of the NHS material is the lack of blood samples for the entire study 
population to assess ACPA-status. However, it has been shown that the demographic and 
exposure characteristics of participants who provided blood samples are similar to those in 
the overall cohorts. [106, 107] The high participation rate in this cohort minimizes the risk of 
selection bias. 
5.2.3 Misclassification of exposure 
It is very unlikely that a misclassification occurred in the analysis of parity (Paper I). 
However, misclassification of the postpartum period during the index-year might have 
occurred as we did not collect detailed information on month of delivery. This 
misclassification is possibly non-differential (generally leading to a dilution of the results), 
which is supported by the different results according to ACPA status. Similarly, we lacked 
detailed information regarding the exact time of the absence of menses (Paper IV), which we 
minimized by excluding all women who did not report a specific age at menopause and by 
restricting our analyses to women aged 50-70 years when the menopause is more likely to 
have already occurred. 
In a case-control study, bias originating from differential recall between cases who have RA 
symptoms at the time of reporting exposures and controls cannot be ruled out. However, we 
do not believe that the main hormonal/reproductive factors (e.g. parity, ever use of OCs or 
PMH) included in our study may suffer from a differential-misclassification of exposure. We 
decided not to include detailed information on PMH and OC use (specific preparations and 
doses), mainly because of the lack of completeness and resulting loss of power for any 
stratified analyses.  
For the NHS, a limitation is the self-reported exposure data, which might lead to 
misclassification of the menopausal factors. However, because the data were collected 
prospectively this potential misclassification of exposure would be non-differential and the 
results would be diluted. 
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5.2.4 Misclassification of disease 
An important requirement for any epidemiological study is a set of well-defined diagnostic 
criteria. Cases included in this thesis, whether from EIRA or from NHS, were mostly 
diagnosed according to the 1987 ACR-criteria [12] which are widely used in clinical practice. 
The limitation of these criteria might be the inability to detect early cases of RA. Cases could 
then be classified as non-cases, which may have occurred predominantly for seronegative 
RA. However, since our analyses were conducted stratifying the cases by serological 
phenotype, we believe that this potential source of bias was minimized. 
It is unlikely that the exposures under study would have had any impact on the inclusion of 
cases. Therefore, this source of misclassification is likely to be non-differential, leading to a 
dilution of our results.  
We do not believe that the emergence of new criteria for RA had an impact on our results. 
Most of the cases in our studies fulfilled both criteria, with only a small fraction (one and 24 
cases in Papers IV and II respectively) having been diagnosed with these more recent but not 
the original criteria.   
For the NHS, the reliance on medical record documentation rather than physical examination 
for the classification of RA cases could result in a misclassification of cases as non-cases. 
This was minimized by censoring those cases with self-reported RA or other connective 
tissue diseases at the date of first report if RA diagnosis could not be confirmed by medical 
records.  
Another issue related to the NHS is that ACPA was not available for all individuals 
diagnosed with RA in the 1980s, prior to its clinical availability. This might lead to a 
potential for misclassification of ACPA-positive RA cases as seronegative cases, which 
would underestimate the associations between menopausal factors and the risk of 
seronegative RA.   
5.2.5 Confounding 
Cases for the EIRA study were matched according to age and residential area. These 
variables were always included in the analyses. Of the potential confounders considered in 
our analyses using material from the EIRA study, smoking was the only factor that affected 
our estimates and therefore adjusted results are shown in most of the tables contained in the 
papers using this material  (Papers I, II and IV). As smoking habits may change over time, it 
is difficult to evaluate this variable in relation to the exposures under study, especially for 
parity and BF practices.   
The strategy used for analyzing the NHS data consisted of multivariate analyses, excluding 
those potential confounders that did not affect the estimates. 
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Both types of studies are limited by the ability to adjust only for confounders that were 
measured in the parent study. Thus unmeasured confounders cannot be included in 
multivariable models, and could explain some of the different results. 
 
5.3 FINAL REMARKS AND FUTURE RESEARCH  
RA is one of the most common autoimmune diseases, with a higher prevalence among 
women. The involvement of hormonal/reproductive factors has long been suspected to be 
related to the pathogenesis of the disease. Not much is known about ACPA-status or genetic 
variables in relation to these hormonal factors. Our study contributes to the knowledge in this 
area by providing a thorough analysis of some of the most important reproductive factors 
using data from two of the largest ongoing studies.  
Our results showed that: parity, the postpartum period and a young age at first birth were 
associated with an increased risk of ACPA-negative RA; both BF and OC use were 
associated with a decreased risk of ACPA-positive RA; postmenopausal women had an 
increased risk of seronegative RA, and women with a history of PMH use had an increased 
risk of seropositive RA in the NHS; and postmenopausal women who were using PMH at 
disease onset had a decreased risk of ACPA-positive RA in the EIRA study.  
The results of this thesis highlight the importance of discriminating between serological 
phenotypes when evaluating risk factors for RA. It would be interesting to explore whether 
some of the hormonal/reproductive factors may also have an impact on the severity of the 
disease. This might be possible because a follow-up study of the cases from the EIRA study 
is currently being conducted.  
A recent study of different specificities in RA has shown that antibodies might be present 
even for the subgroup of ACPA-negative disease. [108] Further studies looking at the 
hormonal/reproductive factors investigated in this thesis in relation to the different 
specificities, beyond the broader group of ACPA-status, would be of interest. 
Why the hormonal/reproductive factors have a different impact depending on the serological 
RA phenotypes remains to be elucidated, and we can only hypothesize about the exact 
biological mechanisms underlying our findings. For these theories to be confirmed, more 
studies including laboratory measurements are required in order to determine the real 
hormonal changes associated with major events in the life of every woman and their impact 
on the onset of RA.  
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6 CONCLUSIONS 
 
 Parous women of reproductive age had an increased risk of ACPA-negative RA. The 
increased risk was mainly due to an increased risk in the postpartum period and young age at 
first birth. 
 Parous women who breastfed their children for more than a year had a decreased risk of 
developing ACPA-positive RA, compared with parous women who breastfed for a period of 
six months or less.  
 Ever and past use of OCs were significantly associated with a decreased risk of developing 
ACPA-positive RA, and we found that this association was stronger for a longer duration of 
use. 
 The association between PMH use among and the risk of seropositive/-negative RA is 
inconclusive. However, a long duration of PMH use might be related to an increased risk of 
seropositive RA. The inconclusive results might be due to unmeasured confounders 
 Our findings of a different impact of hormonal/reproductive factors on the two subsets of RA 
(ACPA-positive and ACPA-negative) add further support to the notion that RA comprises 
two different disease entities with different etiologies. 
 Menopausal factors, are strongly associated with seronegative RA, but not seropositive RA, 
suggesting differences in disease etiology according to serotype. 
 Further research is needed in order to explore the biological mechanisms behind our findings; 
nevertheless, our results regarding hormonal/reproductive factors can contribute to 
understanding the complex etiology of RA and the higher incidence among women. 
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7 SAMMANFATTNING PÅ SVENSKA 
Reumatoid artrit (RA) är en inflammatorisk sjukdom som kännetecknas av kronisk inflammation 
i kroppens leder. Etiologin består av ett komplext samspel mellan genetiska och miljömässiga 
faktorer. RA är vanligare bland kvinnor än bland män och kan uppstå i alla åldrar, men skillnaden 
mellan könen tycks vara störst före klimakteriet. Det har antagits att förändringar i kvinnliga 
hormonnivåer kan vara inblandade i RA-patogenesen. Det övergripande syftet med min 
avhandling var att studera sambandet mellan hormonella/reproduktiva faktorer och risken för RA 
och huruvida sambandet med dessa faktorer skiljer sig mellan olika serologiska fenotyper av 
sjukdomen (baserat på närvaro/frånvaro av antikroppar mot citrullinerade peptider (ACPA) och 
reumatoid-faktor (RF)). 
Denna avhandling bygger på data från två stora studier. Tre artiklar baserades på den svenska 
EIRA (epidemiologisk undersökning av riskfaktorer för reumatoid artrit) studien, en 
befolkningsbaserad fall-kontrollstudie med incidenta RA-fall. Studiepopulationen bestod av 
befolkningen i åldern 18 år och uppåt, boende i vissa geografiska delar av Sverige från 1996. 
Kontrollerna valdes slumpmässigt ur befolkningsregistret med hänsyn tagen till ålder, kön och 
bostadsort. Fall och kontroller besvarade ett detaljerat frågeformulär rörande livsstils- och 
miljöexponeringar. En artikel bygger på Nurses’ Health Study (NHS) som består av två 
prospektiva kohorter av kvinnliga sjuksköterskor i USA. Datainsamlingen i NHS startade 1976 
(kvinnor i åldern 30-55 år) och 1989 (kvinnor i åldern 25-42 år). Båda kohorter följdes upp 
vartannat år via frågeformulär avseende sjukdomar, livsstil och hälsa. 
Enligt våra resultat hade kvinnor, som fött barn i åldrarna 18-44 år, en ökad risk för ACPA-
negativ RA jämfört med kvinnor i samma ålder som inte fött barn. Den ökade risken kunde 
främst förklaras av en förhöjd risk vid tiden efter förlossningen samt ung ålder vid första barnets 
födelse. Äldre förstagångsföderskor hade en minskad risk för ACPA-positiv RA. Kvinnor som 
fött barn och som ammat i över ett år hade en minskad risk för ACPA-positiv RA jämfört med 
kvinnor som ammat sex månader eller mindre. Efter justering för rökning var den skyddande 
effekten inte längre signifikant.  
Kvinnor som någon gång använt p-piller hade en lägre risk för ACPA-positiv RA medan en 
längre duration var signifikant associerad med en minskad risk för båda RA-subtyper. 
Postmenopausala kvinnor hade en fördubblad risk för seronegativ RA jämfört med 
premenopausala kvinnor, men de hade inget samband med insjuknande i seropositiv RA. I NHS 
hade kvinnor med lång postmenopausal hormonbehandling (PMH) en ökad risk för seropositiv 
RA. Slutligen, i EIRA hade postmenopausala kvinnor som använt PMH vid sjukdomsdebut en 
lägre risk för ACPA-positiv RA. Den minskade risken gällde för kvinnor i åldrarna 50-59 år med 
kortvarig användning (<7 år) och endast bland dem med en kombinerad östrogen- och 
gestagenbehandling. 
Ytterligare forskning behövs för att utforska de biologiska mekanismerna bakom våra fynd men 
våra resultat bidrar till kunskapen om hormonella/reproduktiva faktorer och deras inverkan på 
serologiska fenotyper av RA. 
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8 RESUMEN EN ESPAÑOL 
La artritis reumatoide (AR) es una enfermedad crónica inflamatoria que conduce a daño articular 
y destrucción ósea, con una compleja interacción entre factores genéticos y ambientales 
involucrados en su etiología. La AR es más frecuente en mujeres que en hombres en todas las 
edades, pero esta diferencia parece ser mayor antes de la menopausia. Se ha propuesto como 
hipótesis que los cambios en los niveles hormonales en el género femenino podrían estar 
involucrados en la patogénesis de la AR. El objetivo general de esta tesis fue estudiar la 
asociación entre factores hormonales/reproductivos y el riesgo de AR y determinar si estos 
factores se asocian de manera diferente con los fenotipos serológicos de la enfermedad (de 
acuerdo a la presencia o ausencia de anticuerpos contra péptidos citrulinados (ACPA) y contra el 
factor reumatoide (FR)). 
Esta tesis está basada en información obtenida de dos grandes estudios. Tres artículos fueron 
basados en la Investigación Epidemiológica Sueca de AR (Swedish Epidemiological 
Investigation of RA – EIRA), un estudio de casos y controles de base poblacional que comprende 
casos incidentes de AR. La población de estudio fueron personas de 18 o más años de edad, con 
vivienda en diferentes regiones geográficas de Suecia a partir de 1996. Los controles fueron 
elegidos del registro poblacional de manera aleatoria y emparejados a los casos según edad, sexo 
y área residencial. Los casos y controles respondieron un extenso cuestionario a través del cual se 
recolectó información acerca de su estilo de vida y exposiciones ambientales. Un artículo está 
basado en el Estudio sobre la Salud de las Enfermeras (Nurses’ Health Study – NHS) el cual 
consiste en dos cohortes prospectivas de enfermeras en Estados Unidos. La recolección de los 
datos comenzó en 1976 (mujeres entre 30 y 55 años de edad) y 1989 (mujeres entre 25 y 42 años 
de edad). Ambas cohortes del NHS fueron seguidas a través de cuestionarios bienales con 
relación a enfermedades, estilo de vida y prácticas sanitarias. 
De acuerdo con nuestros resultados, las mujeres que tuvieron hijos presentaron un riesgo 
incrementado de AR ACPA-negativa comparadas con las mujeres nulíparas, entre los 18 y 44 
años de edad. Este resultado fue atribuido a un riesgo elevado durante el postparto y a una edad 
temprana al nacimiento del primer(a) hijo(a). Una edad más avanzada al momento del primer 
nacimiento pareció estar asociada con un riesgo menor de AR ACPA-positiva. Las mujeres que 
amamantaron a su(s) hijo(s) por más de un año tuvieron un riesgo menor de AR ACPA-positiva 
comparadas con las mujeres que amamantaron por un periodo menor o igual a seis meses. Esta 
disminución del riesgo no fue significativa al ajustar el análisis por el consumo de cigarrillo.  
El uso de anticonceptivos orales estuvo significativamente asociado con una disminución en el 
riesgo de AR ACPA-positiva, mientras que una larga duración en el uso de los mismos estuvo 
significativamente asociada con una disminución del riesgo para ambos fenotipos de AR. Las 
mujeres postmenopáusicas presentaron un riesgo incrementado de desarrollar AR seronegativa, 
pero no tuvieron asociación con el desarrollo de la AR seropositiva. Las mujeres 
postmenopáusicas, usuarias de terapia de reemplazo hormonal (TRH) de manera prolongada, 
tuvieron un riesgo incrementado de AR seropositiva en el NHS. Finalmente, en el estudio EIRA, 
las mujeres postmenopáusicas que se encontraban usando TRH al inicio de su enfermedad 
tuvieron un riesgo disminuido de AR ACPA-positiva. Esta disminución en el riesgo se presentó 
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principalmente en mujeres entre los 50 y 59 años de edad, con un uso corto de TRH (menor a 7 
años) y sólo entre usuarias de terapia combinada de estrógenos y progestágenos.  
Se requiere investigación adicional para explorar los mecanismos biológicos detrás de nuestros 
hallazgos, pero nuestros resultados contribuyen al entendimiento de los factores 
hormonales/reproductivos y su impacto en los fenotipos serológicos de la AR. 
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9 APPENDIX 
Questions about hormonal/reproductive factors included in the EIRA study. 
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